
|Articles|May 1, 2003
Gatifloxacin approved
Author(s)Scott M. Whitcup, MD, Ed Edelson
CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
5














































